Alpha Cognition’s ZUNVEYL Wins FDA Approval for Alzheimer’s
Company Announcements

Alpha Cognition’s ZUNVEYL Wins FDA Approval for Alzheimer’s

Story Highlights

Alpha Cognition Inc (TSE:ACOG) has released an update.

Alpha Cognition Inc. has announced the FDA approval of ZUNVEYL, a novel oral therapy for treating Alzheimer’s disease, designed to improve tolerability and long-term cognitive function. ZUNVEYL distinguishes itself by targeting the elimination of drug absorption in the GI tract, potentially reducing the side effects that often cause patients to discontinue treatment. The therapy also offers benefits in daily living activities for the nearly 7 million Americans affected by Alzheimer’s.

For further insights into TSE:ACOG stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskAlpha Cognition Plans Nasdaq Listing and $25M Offering
TipRanks Canadian Auto-Generated NewsdeskAlpha Cognition Inc. Appoints New Finance VP
TipRanks Canadian Auto-Generated NewsdeskAlpha Cognition Secures U.S. Patent for Alzheimer’s Drug
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App